Compare FKWL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | GLTO |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 54.5M |
| IPO Year | 1996 | 2020 |
| Metric | FKWL | GLTO |
|---|---|---|
| Price | $4.09 | $25.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $41.00 |
| AVG Volume (30 Days) | 8.0K | ★ 31.5K |
| Earning Date | 02-13-2026 | 03-18-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,508,949.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.05 | N/A |
| 52 Week Low | $3.67 | $2.01 |
| 52 Week High | $7.45 | $38.33 |
| Indicator | FKWL | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 41.76 | 49.95 |
| Support Level | $4.05 | $21.82 |
| Resistance Level | $4.19 | $26.10 |
| Average True Range (ATR) | 0.05 | 2.47 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 28.57 | 30.29 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.